𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Improved but not normalized glucose counter-regulation during glucagon infusion in Type 1 (insulin-dependent) diabetes

✍ Scribed by I. Lager; H. von Schenck; U. Smith


Book ID
104692323
Publisher
Springer
Year
1984
Tongue
English
Weight
574 KB
Volume
26
Category
Article
ISSN
0012-186X

No coin nor oath required. For personal study only.

✦ Synopsis


Glucose counter-regulation during insulin-induced hypoglycaemia was studied in Type 1 diabetic patients without evidence of autonomic neuropathy and compared with that of a non-diabetic control group. The glucose recovery rate following hypoglycaemia was delayed in the diabetic compared with the control subjects and this was most pronounced for the initial, rapid phase of glucose increase (glucose increase in 15 min, control: 1.1 +/- 0.1 versus 0.4 +/- 0.1 mmol/l; p less than 0.01). The release of glucagon during hypoglycaemia was blunted in the diabetic patients (maximal plasma levels, control: 148 +/- 25 versus 70 +/- 10 pg/ml; p less than 0.01). The adrenaline levels were also lower compared with the control subjects (maximal plasma levels, control: 7.23 +/- 1.21 versus 3.27 +/- 0.87 nmol/l; p less than 0.05). To evaluate the importance of the blunted glucagon response for the delayed glucose compensation, glucagon was infused during the hypoglycaemia. Overall glucose recovery rate was improved but did not return to normal. Consequently impaired glucagon release in the diabetic patients cannot alone explain impaired glucoregulation; the lower adrenaline levels and/or an effect of the previous glucose levels per se on hepatic glucose production are probably also of importance.


πŸ“œ SIMILAR VOLUMES


Plasma glucagon and glucagon-like immuno
✍ A. Rovira; F. J. Garrote; J. M. Pascual; M. G. Salvador; J. L. Herrera Pombo; I. πŸ“‚ Article πŸ“… 1985 πŸ› Springer 🌐 English βš– 723 KB

Biogel P-30 filtration of plasma from Type 1 (insulin-dependent) diabetic patients and normal subjects in basal state and after an oral glucose load was assayed with a C-terminal (30 K) and a glucagon-like immunoreactivity-cross-reacting antiserum (R8). Up to four immunoreactive peaks of approximate